Publicaciones en colaboración con investigadores/as de Charité (14)

2023

  1. Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide: Pooled analysis of three randomized trials

    International Journal of Cardiology, Vol. 377, pp. 86-88

2022

  1. Dyskalemia in people at increased risk for heart failure: findings from the heart ‘OMics’ in AGEing (HOMAGE) trial

    ESC Heart Failure, Vol. 9, Núm. 6, pp. 4352-4357

2020

  1. Natural Compound Library Screening Identifies New Molecules for the Treatment of Cardiac Fibrosis and Diastolic Dysfunction

    Circulation, Vol. 141, Núm. 9, pp. 751-767

2019

  1. Myocardial fibrosis as a matter of cell differentiation: Opportunities for new antifibrotic strategies

    European Heart Journal

  2. Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology

    European Journal of Heart Failure, Vol. 21, Núm. 3, pp. 272-285

2018

  1. Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial

    European Journal of Heart Failure, Vol. 20, Núm. 9, pp. 1290-1299

  2. Immunomodulation by adoptive regulatory T-cell transfer improves Coxsackievirus B3-induced myocarditis

    FASEB Journal, Vol. 32, Núm. 11, pp. 6066-6078

  3. Investigating a biomarker-driven approach to target collagen turnover in diabetic heart failure with preserved ejection fraction patients. Effect of torasemide versus furosemide on serum C-terminal propeptide of procollagen type I (DROP-PIP trial)

    European Journal of Heart Failure, Vol. 20, Núm. 3, pp. 460-470

2017

  1. Impact of acute hypertension transients on diastolic function in patients with heart failure with preserved ejection fraction

    Cardiovascular Research, Vol. 113, Núm. 8, pp. 906-914

  2. Risk for incident heart failure: A subject-level meta-analysis from the heart "OMics" in AGEing (HOMAGE) study

    Journal of the American Heart Association, Vol. 6, Núm. 5

2016

  1. Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment

    Nature Communications, Vol. 7

2014

  1. New strategies for heart failure with preserved ejection fraction: The importance of targeted therapies for heart failure phenotypes

    European Heart Journal, Vol. 35, Núm. 40, pp. 2797-2811d

2013

  1. Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model

    Circulation: Heart Failure, Vol. 6, Núm. 6, pp. 1239-1249

  2. Osteopontin-mediated myocardial fibrosis in heart failure: A role for lysyl oxidase?

    Cardiovascular Research, Vol. 99, Núm. 1, pp. 111-120